Tirzepatide is a unique dual RA of both the GLP-1 and GIP receptors, which significantly reduces HbA1c levels and body weight in patients with T2DM and obesity. Its once-weekly dosing and potential cardiovascular benefits make Tirzepatide an attractive option for treating these conditions. Studies show that Tirzepatide reduces appetite, improves control of eating, and reduces food cravings in addition to improving glycemic control.